Skip to content
MedsAcross

Medicine

Pancreaze 61500 units/10500 units/35500 units delayed-release capsule

Available on requestPrescription onlyUS FDA

Pancreaze 61500 units/10500 units/35500 units delayed-release capsule is a prescription medicine containing Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for oral use, marketed by Vivus, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store PANCREAZE at room temperature between 15ºC and 25ºC (59°F to 77°F)…

Key facts

Active ingredient (INN)
Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease
Brand
Pancreaze
Strength
61500 units/10500 units/35500 units
Dosage form
Delayed-release capsule
Route
Oral
Packs
1 bottle
Marketing authorisation holder
Vivus
Manufacturer
Vivus
Origin register
US FDA, United States
Storage
Store PANCREAZE at room temperature between 15ºC and 25ºC (59°F to 77°F), excursion permitted up to 40ºC (104°F) for 24 hours. After opening, keep bottle tightly closed between uses to protect from moisture. Store and dispense PANCREAZE in the original container.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3002.15Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
12 April 2010
Identifiers
RxCUI 1806919, 1806921, 1806924 +7DailyMed set ID e8f5d2fe-728d-42af-99a6-83dddc6539c5NDC 62541-403Application BLA022523

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle, glass in 1 carton / 100 capsule, delayed release in 1 bottle, glass62541-403-10Vivus12 April 2010

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease

Clinical summary

Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease is a fixed-dose combination medicine indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. MedsAcross supplies Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Pancreaze 61500 units/10500 units/35500 units delayed-release capsule for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.